SCHEMBL9926064

SCHEMBL9926064

Cc1cccc(N2CCN(C(=O)[C@@H]3CN(S(=O)(=O)c4ccc(Cl)s4)C[C@H]3c3ccccc3)CC2)c1C

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.53
AR P10275 2/20 0.49
KMT2A Q03164 4/20 0.45
MAPK1 P28482 3/20 0.45
TSHR P16473 2/20 0.45
LMNA P02545 1/20 0.45
MAPT P10636 5/20 0.45
ALDH1A1 P00352 3/20 0.45
NR4A1 P22736 1/20 0.45
ESR2 Q92731 1/20 0.45
NPSR1 Q6W5P4 2/20 0.43
MEN1 O00255 2/20 0.43
GAA P10253 1/20 0.43
MCOLN3 Q8TDD5 1/20 0.43
MC4R P32245 4/20 0.43
POLB P06746 1/20 0.42
TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5268066 0.88 SMN1; SMN2 (0.48) SMN1; SMN2ARKMT2ATSHRMAPT
SCHEMBL9926081 0.88 SMN1; SMN2 (0.48) SMN1; SMN2ARKMT2ATSHRMAPT
SCHEMBL9926101 0.87 SMN1; SMN2 (0.47) SMN1; SMN2ARKMT2AMAPK1TSHR
SCHEMBL5264577 0.87 AR (0.46) SMN1; SMN2ARKMT2AMAPK1TSHR
SCHEMBL9926078 0.87 AR (0.46) SMN1; SMN2ARKMT2AMAPK1TSHR
SCHEMBL5341354 0.86 KMT2A (0.64) SMN1; SMN2KMT2AMAPK1TSHRLMNA
SCHEMBL13987538 0.86 KMT2A (0.64) SMN1; SMN2KMT2AMAPK1TSHRLMNA
SCHEMBL9926054 0.86 LMNA (0.53) SMN1; SMN2ARKMT2ATSHRLMNA
SCHEMBL5264583 0.86 LMNA (0.53) SMN1; SMN2ARKMT2ATSHRLMNA
SCHEMBL9925999 0.86 SIGMAR1 (0.53) SMN1; SMN2KMT2AMAPK1TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836180-B1 SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS SANOFI SA (FR) 2012-06-13 EP disclosed
US-7468369-B2 Sulfonyl pyrrolidines, method for producing the same and their use as drugs SANOFI-AVENTIS (FR) 2008-12-23 US disclosed
US-7468369-B2 Sulfonyl pyrrolidines, method for producing the same and their use as drugs SANOFI-AVENTIS (FR) 2008-12-23 US disclosed
US-20080045540-A1 SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-21 US disclosed
US-20080045540-A1 SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045540-A1 SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS SLC5A1, SLC5A2, KCNJ1 SMN1; SMN2 1865/4885AR 4287/4885KMT2A 4211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.